avacta group plc - review of the ava6000 clinical trial’s phase 1a data
Published 10 months ago • 2.7K plays • Length 59:39Download video MP4
Download video MP3
Similar videos
-
1:03:46
avacta group plc - investor presentation
-
1:33
just the facts: tryptamine therapeutics’ trp-8803 clears phase 1b safety trial
-
0:31
pasithea: advancing therapeutic solutions for nf1 and cns disorders
-
0:31
can-fite biopharma: developing treatments for liver cancer
-
4:40
diagnosing cca
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
47:20
qfr: the next-generation diagnostic tool for epicardial and microvascular disease in the cathlab
-
50:32
precision medicine for ovarian cancer (2021)
-
1:02:17
breast cancer hopa bcop review
-
0:31
os therapies: transforming cancer treatment with next-generation immunotherapies for osteosarcoma
-
10:36
hope for lung cancer patients: cypath lung test's impact
-
5:01
dr. dana ataya - “end the confusion”
-
8:07
highly anticipated data from the solo-1 trial
-
0:31
revolutionizing early cancer detection: introducing cypath® lung by bioaffinity technologies
-
![[tctap 2023] clinical science - all about new data from amc](https://i.ytimg.com/vi/NZdvw4VUCnw/mqdefault.jpg)
1:16:36
[tctap 2023] clinical science - all about new data from amc
-
9:29
the latest from augusta oncology's cpan chapter
-
1:16
developing early screening test for ovarian cancer
-
1:26
actimab-a update
-
0:53
dr. puhalla on the value of biosimilars in oncology
-
2:21
180 updated phase 1 results of teclistamab, a bcma x cd3 bispecific antibody
-
27:39
novel therapeutics in ovarian cancer: what to watch
-
5:02
the value of a sitc membership